Novo Nordisk A/S (NVO)
46.77
+1.65
(+3.66%)
USD |
NYSE |
Sep 02, 16:00
46.77
0.00 (0.00%)
After-Hours: 16:36
Novo Nordisk Research and Development Expense (Annual) : 6.838B for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 6.838B |
| December 31, 2024 | 5.514B |
| December 31, 2023 | 4.262B |
| December 31, 2022 | 3.074B |
| December 31, 2021 | 2.589B |
| December 31, 2020 | 2.097B |
| December 31, 2019 | 1.937B |
| December 31, 2018 | 2.148B |
| December 31, 2017 | 2.013B |
| December 31, 2016 | 2.027B |
| December 31, 2015 | 1.923B |
| December 31, 2014 | 2.286B |
| December 31, 2013 | 2.006B |
| December 31, 2012 | 1.800B |
| December 31, 2011 | 1.679B |
| December 31, 2010 | 1.624B |
| December 31, 2009 | 1.370B |
| December 31, 2008 | 1.396B |
| December 31, 2007 | 1.264B |
| December 31, 2006 | 1.012B |
| December 31, 2005 | 809.07M |
| December 31, 2004 | 690.31M |
| December 31, 2003 | 607.76M |
| Date | Value |
|---|---|
| December 31, 2002 | 500.75M |
| December 31, 2001 | 458.56M |
| December 31, 2000 | 398.44M |
| December 31, 1999 | 448.37M |
| December 31, 1998 | 477.27M |
| December 31, 1997 | 386.80M |
| December 31, 1996 | 358.59M |
| December 31, 1995 | 328.37M |
| December 31, 1994 | 272.87M |
| December 31, 1993 | 269.19M |
| December 31, 1992 | 252.42M |
| December 31, 1991 | 210.47M |
| December 31, 1990 | 193.16M |
| December 31, 1989 | 135.35M |
| December 31, 1988 | 101.14M |
| December 31, 1987 | 82.63M |
| December 31, 1986 | 59.47M |
| December 31, 1985 | 42.80M |
| December 31, 1984 | 35.94M |
| December 31, 1983 | 33.44M |
| December 31, 1982 | 30.69M |
| December 31, 1981 | 29.19M |
| December 31, 1980 | 29.47M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| AstraZeneca PLC | 13.84B |
| Johnson & Johnson | 14.83B |
| Eli Lilly & Co. | 13.34B |
| Merck & Co., Inc. | 12.51B |
| Novartis AG | 10.74B |